Human Papilloma Virus

Human Papillomavirus (HPV) is a small, non-enveloped DNA virus with a circular genome that replicates in the nuclei of infected epithelial cells. The viral life cycle involves distinct phases, including viral entry, genome replication, and the production of viral particles. HPVs have evolved sophisticated mechanisms to evade host immune responses and establish persistent infections. High-risk HPV types, particularly HPV 16 and 18, are associated with oncogenic potential due to the expression of two key viral oncoproteins: E6 and E7. E6 promotes the degradation of the tumor suppressor protein p53, while E7 disrupts the function of the retinoblastoma protein (pRb), leading to uncontrolled cell proliferation. These interactions contribute to the development of HPV-associated cancers, including cervical and oropharyngeal cancers. Therapeutic approaches for HPV-related cancers include surgical interventions, radiation therapy, and antiviral drugs. Research into novel antiviral agents targeting specific steps of the viral life cycle is ongoing, aiming to inhibit viral replication and reduce the risk of cancer progression. Immunotherapies, such as therapeutic vaccines and immune checkpoint inhibitors, focus on enhancing the host immune response to clear HPV-infected cells. Understanding the molecular intricacies of HPV-host interactions is essential for developing targeted therapies and improving outcomes for individuals with HPV-associated diseases. Ongoing research aims to unravel the complexities of HPV pathogenesis, identify new therapeutic targets, and advance innovative approaches for the prevention and treatment of HPV infections and their associated cancers.